Blood-Borne Diseases

A recent study suggests that Ebola virus RNA can remain in the genital tract for more than 2 years following the acute infection period.

A recent study finds that the use of sofosbuvir-based direct-acting antivirals for HCV treatment was effective and well-tolerated in elderly patients.

The decision date for a NDA for a new hepatitis B vaccine, Dynavax’s Heplisav-B, has been delayed, as the FDA asked for more post-marketing study information on the vaccine.

Despite the progress that has been made, more research is needed on cancer prevention, hepatitis B, and human papillomavirus vaccines.

With IV drug use accounting for 60% of new infections, treatment for individuals in this population is necessary to stave off new infections.

New HIV drugs, vaccine regulations in France, correlations between intestinal viruses & type 1 diabetes, the susceptibility of Florida mosquitoes to transmit chikungunya, and an evaluation of the risk of hepatitis B reactivation in veterans on direct-acting antiviral therapy make up our Top 5 articles for the week of July 30, 2017.

The US Food and Drug Administration approved Mavyret for adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis.

A recent study finds that HBV reactivation occurs earlier and is more severe in HBV/HCV coinfected patients treated with DAA therapy compared with patients treated with IFN-based therapy.

In a 12-1 vote, the FDA’s Vaccines and Related Biological Products Advisory Committee supported the safety data of a new potential hepatitis B vaccine.

After Italy’s parliamentary decision to mandate vaccines, France health officials follow suit, requiring parents to vaccinate their children against 11 common illnesses starting in 2018.

A new study published in the Journal of Hepatology evaluates the risk of HBV reactivation in veterans receiving direct-acting antiviral therapy.

Scientists make an interesting connection between bats and detecting undiscovered disease.

Study finds that hepatitis C patients who had reached sustained virologic response using direct-acting antiviral drugs show a considerably reduced risk of the most common type of liver cancer.

Ebola virus tracking and mechanisms to detect threats to our national food supply are highlighted.

A research team from the Netherlands turns to deep sequencing technology to detect hepatitis C virus resistant variants.

A naturally occurring compound in plums has been found to block the entry of the hepatitis C virus into cultured liver cells.

The World Health Organization has officially declared that the recent Ebola outbreak in the Democratic Republic of Congo is over.

Following a request from the US Food and Drug Administration (FDA), Endo Pharmaceuticals has pulled its opioid agonist Opana ER (oxymorphone hydrochloride extended release).

How 8 years of poor disinfection exposed a darker side of Air Force medical practices.

A recent report coming from the O’Neill Institute for National & Global Health Law takes a closer look at the tools needed to achieve hepatitis C elimination in the United States.

A new study finds hepatitis C virus (HCV) infection to be associated with a 70% increased rate of mortality in in-hospital patients with invasive pneumococcal disease (IPD).

Seniors are at increased risk of hepatitis B, hepatitis C, and HIV. Prevention and early detection of potential infection are critical to avoiding long-term impact.

The results of a recent Phase IB study show that the novel Ebola vaccine, V920, was well-tolerated and “stimulated a rapid onset of binding and neutralizing antibodies,” which persisted for up to 1 year.

Researchers from the UNC Lineberger Comprehensive Cancer Center elucidate the mode of action of #NS5A inhibitors, and learn more about the half-life of RCs in hepatitis C viruses.

New drugs for HIV, the growing rate of antibiotic resistance, a new hepatitis C treatment option, and updates on the Ebola outbreak and Lyme disease diagnostics, make up the Top 5 articles for this week.